Global Peptide Cancer Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Global Peptide Cancer Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

Table of Contents
1 Study Coverage
1.1 Peptide Cancer Vaccine Product Introduction
1.2 Market by Pipeline
1.2.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Pipeline
1.2.2 ITK-1
1.2.3 GRN-1201
1.2.4 TPIV200
1.2.5 TPIV110
1.2.6 UV1
1.2.7 Galinpepimut-S
1.2.8 TARP 27-35
1.2.9 HER-Vaxx
1.2.10 Vx-001
1.2.11 Others
1.3 Market by Application
1.3.1 Global Peptide Cancer Vaccine Market Size Growth Rate by Application
1.3.2 Breast Cancer
1.3.3 Lung Cancer
1.3.4 Melanoma
1.3.5 Prostate Cancer
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Peptide Cancer Vaccine Market Size Estimates and Forecasts
2.1.1 Global Peptide Cancer Vaccine Revenue 2016-2027
2.1.2 Global Peptide Cancer Vaccine Sales 2016-2027
2.2 Peptide Cancer Vaccine Market Size by Region: 2021 Versus 2027
2.3 Peptide Cancer Vaccine Sales by Region (2016-2027)
2.3.1 Global Peptide Cancer Vaccine Sales by Region: 2016-2021
2.3.2 Global Peptide Cancer Vaccine Sales Forecast by Region (2022-2027)
2.3.3 Global Peptide Cancer Vaccine Sales Market Share by Region (2016-2027)
2.4 Peptide Cancer Vaccine Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Peptide Cancer Vaccine Revenue by Region: 2016-2021
2.4.2 Global Peptide Cancer Vaccine Revenue Forecast by Region (2022-2027)
2.4.3 Global Peptide Cancer Vaccine Revenue Market Share by Region (2016-2027)
3 Global Peptide Cancer Vaccine by Manufacturers
3.1 Global Top Peptide Cancer Vaccine Manufacturers by Sales
3.1.1 Global Peptide Cancer Vaccine Sales by Manufacturer (2016-2021)
3.1.2 Global Peptide Cancer Vaccine Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Peptide Cancer Vaccine Manufacturers by Revenue
3.2.1 Global Peptide Cancer Vaccine Revenue by Manufacturer (2016-2021)
3.2.2 Global Peptide Cancer Vaccine Revenue Share by Manufacturer (2016-2021)
3.3 Global Peptide Cancer Vaccine Price by Manufacturer (2016-2021)
3.4 Competitive Landscape
3.4.1 Key Peptide Cancer Vaccine Manufacturers Covered: Ranking by Revenue
3.4.2 Global Peptide Cancer Vaccine Market Concentration Ratio (CR5 and HHI) & (2016-2021)
3.4.3 Global Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Peptide Cancer Vaccine Manufacturing Base Distribution, Product Type
3.5.1 Peptide Cancer Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Peptide Cancer Vaccine Product Type
3.5.3 Date of International Manufacturers Enter into Peptide Cancer Vaccine Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Boston Biomedical
4.1.1 Boston Biomedical Corporation Information
4.1.2 Boston Biomedical Description, Business Overview
4.1.3 Boston Biomedical Peptide Cancer Vaccine Products Offered
4.1.4 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.1.5 Boston Biomedical Peptide Cancer Vaccine Revenue by Product
4.1.6 Boston Biomedical Peptide Cancer Vaccine Revenue by Application
4.1.7 Boston Biomedical Peptide Cancer Vaccine Revenue by Geographic Area
4.1.8 Boston Biomedical Peptide Cancer Vaccine Revenue by Sales Channel
4.1.9 Boston Biomedical Recent Development
4.2 Ultimovacs
4.2.1 Ultimovacs Corporation Information
4.2.2 Ultimovacs Description, Business Overview
4.2.3 Ultimovacs Peptide Cancer Vaccine Products Offered
4.2.4 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.2.5 Ultimovacs Peptide Cancer Vaccine Revenue by Product
4.2.6 Ultimovacs Peptide Cancer Vaccine Revenue by Application
4.2.7 Ultimovacs Peptide Cancer Vaccine Revenue by Geographic Area
4.2.8 Ultimovacs Peptide Cancer Vaccine Revenue by Sales Channel
4.2.9 Ultimovacs Recent Development
4.3 BrightPath Biotherapeutics
4.3.1 BrightPath Biotherapeutics Corporation Information
4.3.2 BrightPath Biotherapeutics Description, Business Overview
4.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Products Offered
4.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.3.5 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue by Product
4.3.6 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue by Application
4.3.7 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue by Geographic Area
4.3.8 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue by Sales Channel
4.3.9 BrightPath Biotherapeutics Recent Development
4.4 TapImmune
4.4.1 TapImmune Corporation Information
4.4.2 TapImmune Description, Business Overview
4.4.3 TapImmune Peptide Cancer Vaccine Products Offered
4.4.4 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.4.5 TapImmune Peptide Cancer Vaccine Revenue by Product
4.4.6 TapImmune Peptide Cancer Vaccine Revenue by Application
4.4.7 TapImmune Peptide Cancer Vaccine Revenue by Geographic Area
4.4.8 TapImmune Peptide Cancer Vaccine Revenue by Sales Channel
4.4.9 TapImmune Recent Development
4.5 Immatics
4.5.1 Immatics Corporation Information
4.5.2 Immatics Description, Business Overview
4.5.3 Immatics Peptide Cancer Vaccine Products Offered
4.5.4 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.5.5 Immatics Peptide Cancer Vaccine Revenue by Product
4.5.6 Immatics Peptide Cancer Vaccine Revenue by Application
4.5.7 Immatics Peptide Cancer Vaccine Revenue by Geographic Area
4.5.8 Immatics Peptide Cancer Vaccine Revenue by Sales Channel
4.5.9 Immatics Recent Development
4.6 Sellas
4.6.1 Sellas Corporation Information
4.6.2 Sellas Description, Business Overview
4.6.3 Sellas Peptide Cancer Vaccine Products Offered
4.6.4 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.6.5 Sellas Peptide Cancer Vaccine Revenue by Product
4.6.6 Sellas Peptide Cancer Vaccine Revenue by Application
4.6.7 Sellas Peptide Cancer Vaccine Revenue by Geographic Area
4.6.8 Sellas Recent Development
4.7 Imugene
4.7.1 Imugene Corporation Information
4.7.2 Imugene Description, Business Overview
4.7.3 Imugene Peptide Cancer Vaccine Products Offered
4.7.4 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.7.5 Imugene Peptide Cancer Vaccine Revenue by Product
4.7.6 Imugene Peptide Cancer Vaccine Revenue by Application
4.7.7 Imugene Peptide Cancer Vaccine Revenue by Geographic Area
4.7.8 Imugene Recent Development
4.8 VAXON Biotech
4.8.1 VAXON Biotech Corporation Information
4.8.2 VAXON Biotech Description, Business Overview
4.8.3 VAXON Biotech Peptide Cancer Vaccine Products Offered
4.8.4 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.8.5 VAXON Biotech Peptide Cancer Vaccine Revenue by Product
4.8.6 VAXON Biotech Peptide Cancer Vaccine Revenue by Application
4.8.7 VAXON Biotech Peptide Cancer Vaccine Revenue by Geographic Area
4.8.8 VAXON Biotech Recent Development
4.9 Generex Biotechnology
4.9.1 Generex Biotechnology Corporation Information
4.9.2 Generex Biotechnology Description, Business Overview
4.9.3 Generex Biotechnology Peptide Cancer Vaccine Products Offered
4.9.4 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.9.5 Generex Biotechnology Peptide Cancer Vaccine Revenue by Product
4.9.6 Generex Biotechnology Peptide Cancer Vaccine Revenue by Application
4.9.7 Generex Biotechnology Peptide Cancer Vaccine Revenue by Geographic Area
4.9.8 Generex Biotechnology Recent Development
4.10 ISA Pharmaceuticals
4.10.1 ISA Pharmaceuticals Corporation Information
4.10.2 ISA Pharmaceuticals Description, Business Overview
4.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Products Offered
4.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.10.5 ISA Pharmaceuticals Peptide Cancer Vaccine Revenue by Product
4.10.6 ISA Pharmaceuticals Peptide Cancer Vaccine Revenue by Application
4.10.7 ISA Pharmaceuticals Peptide Cancer Vaccine Revenue by Geographic Area
4.10.8 ISA Pharmaceuticals Recent Development
4.11 OncoTherapy Science
4.11.1 OncoTherapy Science Corporation Information
4.11.2 OncoTherapy Science Description, Business Overview
4.11.3 OncoTherapy Science Peptide Cancer Vaccine Products Offered
4.11.4 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2016-2021)
4.11.5 OncoTherapy Science Peptide Cancer Vaccine Revenue by Product
4.11.6 OncoTherapy Science Peptide Cancer Vaccine Revenue by Application
4.11.7 OncoTherapy Science Peptide Cancer Vaccine Revenue by Geographic Area
4.11.8 OncoTherapy Science Recent Development
5 Breakdown Data by Type
5.1 Global Peptide Cancer Vaccine Sales by Pipeline (2016-2027)
5.1.1 Global Peptide Cancer Vaccine Sales by Pipeline (2016-2021)
5.1.2 Global Peptide Cancer Vaccine Sales Forecast by Pipeline (2022-2027)
5.1.3 Global Peptide Cancer Vaccine Sales Market Share by Pipeline (2016-2027)
5.2 Global Peptide Cancer Vaccine Revenue Forecast by Pipeline (2016-2027)
5.2.1 Global Peptide Cancer Vaccine Revenue by Pipeline (2016-2021)
5.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Pipeline (2022-2027)
5.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Pipeline (2016-2027)
5.3 Peptide Cancer Vaccine Average Selling Price (ASP) by Pipeline (2016-2027)
6 Breakdown Data by Application
6.1 Global Peptide Cancer Vaccine Sales by Application (2016-2027)
6.1.1 Global Peptide Cancer Vaccine Sales by Application (2016-2021)
6.1.2 Global Peptide Cancer Vaccine Sales Forecast by Application (2022-2027)
6.1.3 Global Peptide Cancer Vaccine Sales Market Share by Application (2016-2027)
6.2 Global Peptide Cancer Vaccine Revenue Forecast by Application (2016-2027)
6.2.1 Global Peptide Cancer Vaccine Revenue by Application (2016-2021)
6.2.2 Global Peptide Cancer Vaccine Revenue Forecast by Application (2022-2027)
6.2.3 Global Peptide Cancer Vaccine Revenue Market Share by Application (2016-2027)
6.3 Peptide Cancer Vaccine Average Selling Price (ASP) by Application (2016-2027)
7 North America
7.1 North America Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
7.2 North America Peptide Cancer Vaccine Market Facts & Figures by Country
7.2.1 North America Peptide Cancer Vaccine Sales by Country (2016-2027)
7.2.2 North America Peptide Cancer Vaccine Revenue by Country (2016-2027)
7.3 North America Peptide Cancer Vaccine Sales by Pipeline
7.4 North America Peptide Cancer Vaccine Sales by Application
8 Asia-Pacific
8.1 Asia-Pacific Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
8.2 Asia-Pacific Peptide Cancer Vaccine Market Facts & Figures by Region
8.2.1 Asia-Pacific Peptide Cancer Vaccine Sales by Region (2016-2027)
8.2.2 Asia-Pacific Peptide Cancer Vaccine Revenue by Region (2016-2027)
8.3 Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline
8.4 Asia-Pacific Peptide Cancer Vaccine Sales by Application
9 Europe
9.1 Europe Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
9.2 Europe Peptide Cancer Vaccine Market Facts & Figures by Country
9.2.1 Europe Peptide Cancer Vaccine Sales by Country (2016-2027)
9.2.2 Europe Peptide Cancer Vaccine Revenue by Country (2016-2027)
9.3 Europe Peptide Cancer Vaccine Sales by Pipeline
9.4 Europe Peptide Cancer Vaccine Sales by Application
10 Latin America
10.1 Latin America Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
10.2 Latin America Peptide Cancer Vaccine Market Facts & Figures by Country
10.2.1 Latin America Peptide Cancer Vaccine Sales by Country (2016-2027)
10.2.2 Latin America Peptide Cancer Vaccine Revenue by Country (2016-2027)
10.3 Latin America Peptide Cancer Vaccine Sales by Pipeline
10.4 Latin America Peptide Cancer Vaccine Sales by Application
11 Middle East and Africa
11.1 Middle East and Africa Peptide Cancer Vaccine Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Peptide Cancer Vaccine Market Facts & Figures by Country
11.2.1 Middle East and Africa Peptide Cancer Vaccine Sales by Country (2016-2027)
11.2.2 Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2016-2027)
11.3 Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline
11.4 Middle East and Africa Peptide Cancer Vaccine Sales by Application
12 Supply Chain and Sales Channel Analysis
12.1 Peptide Cancer Vaccine Supply Chain Analysis
12.2 Peptide Cancer Vaccine Key Raw Materials and Upstream Suppliers
12.3 Peptide Cancer Vaccine Clients Analysis
12.4 Peptide Cancer Vaccine Sales Channel and Sales Model Analysis
12.4.1 Peptide Cancer Vaccine Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Peptide Cancer Vaccine Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Peptide Cancer Vaccine Distributors
13 Market Dynamics
13.1 Peptide Cancer Vaccine Market Drivers
13.2 Peptide Cancer Vaccine Market Opportunities
13.3 Peptide Cancer Vaccine Market Challenges
13.4 Peptide Cancer Vaccine Market Restraints
13.5 Porter's Five Forces Analysis
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
Table 1. Global Peptide Cancer Vaccine Market Size Growth Rate by Type (US$ Million): 2021 VS 2027
Table 2. Major Manufacturers of ITK-1
Table 3. Major Manufacturers of GRN-1201
Table 4. Major Manufacturers of TPIV200
Table 5. Major Manufacturers of TPIV110
Table 6. Major Manufacturers of UV1
Table 7. Major Manufacturers of Galinpepimut-S
Table 8. Major Manufacturers of TARP 27-35
Table 9. Major Manufacturers of HER-Vaxx
Table 10. Major Manufacturers of Vx-001
Table 11. Major Manufacturers of Others
Table 12. Global Peptide Cancer Vaccine Market Size Growth by Application (US$ Million): 2021 VS 2027
Table 13. Global Peptide Cancer Vaccine Market Size by Region (US$ Million): 2021 VS 2027
Table 14. Global Peptide Cancer Vaccine Sales by Region (2016-2021) & (K Doses)
Table 15. Global Peptide Cancer Vaccine Sales Forecast by Region (2022-2027) & (K Doses)
Table 16. Global Peptide Cancer Vaccine Revenue by Region (2016-2021) & (US$ Million)
Table 17. Global Peptide Cancer Vaccine Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 18. Global Peptide Cancer Vaccine Sales by Manufacturer (2016-2021) & (K Doses)
Table 19. Global Peptide Cancer Vaccine Sales Share by Manufacturer (2016-2021)
Table 20. Peptide Cancer Vaccine Revenue by Manufacturer (2016-2021) & (US$ Million)
Table 21. Peptide Cancer Vaccine Revenue Share by Manufacturer (2016-2021)
Table 22. Key Manufacturers Peptide Cancer Vaccine Price (2016-2021) & (USD/Dose)
Table 23. Ranking of Global Top Peptide Cancer Vaccine Manufacturers by Revenue (US$ Million) in 2020
Table 24. Global Peptide Cancer Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 25. Global Peptide Cancer Vaccine by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2020)
Table 26. Peptide Cancer Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 27. Manufacturers Peptide Cancer Vaccine Product Type
Table 28. Date of International Manufacturers Enter into Peptide Cancer Vaccine Market
Table 29. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 30. Boston Biomedical Corporation Information
Table 31. Boston Biomedical Description and Business Overview
Table 32. Boston Biomedical Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 33. Boston Biomedical Peptide Cancer Vaccine Product
Table 34. Boston Biomedical Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 35. Boston Biomedical Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 36. Boston Biomedical Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 37. Boston Biomedical Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 38. Boston Biomedical Recent Development
Table 39. Ultimovacs Corporation Information
Table 40. Ultimovacs Description and Business Overview
Table 41. Ultimovacs Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 42. Ultimovacs Peptide Cancer Vaccine Product
Table 43. Ultimovacs Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 44. Ultimovacs Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 45. Ultimovacs Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 46. Ultimovacs Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 47. Ultimovacs Recent Development
Table 48. BrightPath Biotherapeutics Corporation Information
Table 49. BrightPath Biotherapeutics Description and Business Overview
Table 50. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 51. BrightPath Biotherapeutics Peptide Cancer Vaccine Product
Table 52. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 53. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 54. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 55. BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 56. BrightPath Biotherapeutics Recent Development
Table 57. TapImmune Corporation Information
Table 58. TapImmune Description and Business Overview
Table 59. TapImmune Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 60. TapImmune Peptide Cancer Vaccine Product
Table 61. TapImmune Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 62. TapImmune Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 63. TapImmune Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 64. TapImmune Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 65. TapImmune Recent Development
Table 66. Immatics Corporation Information
Table 67. Immatics Description and Business Overview
Table 68. Immatics Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 69. Immatics Peptide Cancer Vaccine Product
Table 70. Immatics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 71. Immatics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 72. Immatics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 73. Immatics Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Sales Channel
Table 74. Immatics Recent Development
Table 75. Sellas Corporation Information
Table 76. Sellas Description and Business Overview
Table 77. Sellas Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 78. Sellas Peptide Cancer Vaccine Product
Table 79. Sellas Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 80. Sellas Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 81. Sellas Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 82. Sellas Recent Development
Table 83. Imugene Corporation Information
Table 84. Imugene Description and Business Overview
Table 85. Imugene Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 86. Imugene Peptide Cancer Vaccine Product
Table 87. Imugene Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 88. Imugene Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 89. Imugene Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 90. Imugene Recent Development
Table 91. VAXON Biotech Corporation Information
Table 92. VAXON Biotech Description and Business Overview
Table 93. VAXON Biotech Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 94. VAXON Biotech Peptide Cancer Vaccine Product
Table 95. VAXON Biotech Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 96. VAXON Biotech Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 97. VAXON Biotech Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 98. VAXON Biotech Recent Development
Table 99. Generex Biotechnology Corporation Information
Table 100. Generex Biotechnology Description and Business Overview
Table 101. Generex Biotechnology Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 102. Generex Biotechnology Peptide Cancer Vaccine Product
Table 103. Generex Biotechnology Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 104. Generex Biotechnology Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 105. Generex Biotechnology Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 106. Generex Biotechnology Recent Development
Table 107. ISA Pharmaceuticals Corporation Information
Table 108. ISA Pharmaceuticals Description and Business Overview
Table 109. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 110. ISA Pharmaceuticals Peptide Cancer Vaccine Product
Table 111. ISA Pharmaceuticals Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 112. ISA Pharmaceuticals Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 113. ISA Pharmaceuticals Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 114. ISA Pharmaceuticals Recent Development
Table 115. OncoTherapy Science Corporation Information
Table 116. OncoTherapy Science Description and Business Overview
Table 117. OncoTherapy Science Peptide Cancer Vaccine Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2016-2021)
Table 118. OncoTherapy Science Peptide Cancer Vaccine Product
Table 119. OncoTherapy Science Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Product
Table 120. OncoTherapy Science Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Application
Table 121. OncoTherapy Science Peptide Cancer Vaccine Revenue (US$ Million) and Market Share by Geographic Area
Table 122. OncoTherapy Science Recent Development
Table 123. Global Peptide Cancer Vaccine Sales by Pipeline (2016-2021) & (K Doses)
Table 124. Global Peptide Cancer Vaccine Sales Forecast by Pipeline (2022-2027) & (K Doses)
Table 125. Global Peptide Cancer Vaccine Revenue by Pipeline (2016-2021) & (US$ Million)
Table 126. Global Peptide Cancer Vaccine Revenue Forecast by Pipeline (2022-2027) & (US$ Million)
Table 127. Global Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 128. Global Peptide Cancer Vaccine Sales Forecast by Application (2022-2027) & (K Doses)
Table 129. Global Peptide Cancer Vaccine Revenue by Application (2016-2021) & (US$ Million)
Table 130. Global Peptide Cancer Vaccine Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 131. North America Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 132. North America Peptide Cancer Vaccine Sales by Country (2022-2027) & (K Doses)
Table 133. North America Peptide Cancer Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 134. North America Peptide Cancer Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 135. North America Peptide Cancer Vaccine Sales by Pipeline (2016-2021) & (K Doses)
Table 136. North America Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 137. Asia-Pacific Peptide Cancer Vaccine Sales by Region (2016-2021) & (K Doses)
Table 138. Asia-Pacific Peptide Cancer Vaccine Sales by Region (2022-2027) & (K Doses)
Table 139. Asia-Pacific Peptide Cancer Vaccine Revenue by Region (2016-2027) & (US$ Million)
Table 140. Asia-Pacific Peptide Cancer Vaccine Revenue by Region (2022-2027) & (US$ Million)
Table 141. Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2016-2021) & (K Doses)
Table 142. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 143. Europe Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 144. Europe Peptide Cancer Vaccine Sales by Country (2022-2027) & (K Doses)
Table 145. Europe Peptide Cancer Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 146. Europe Peptide Cancer Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 147. Europe Peptide Cancer Vaccine Sales by Pipeline (2016-2021) & (K Doses)
Table 148. Europe Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 149. Latin America Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 150. Latin America Peptide Cancer Vaccine Sales by Country (2022-2027) & (K Doses)
Table 151. Latin America Peptide Cancer Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 152. Latin America Peptide Cancer Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 153. Latin America Peptide Cancer Vaccine Sales by Pipeline (2016-2021) & (K Doses)
Table 154. Latin America Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 155. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2016-2021) & (K Doses)
Table 156. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2022-2027) & (K Doses)
Table 157. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2016-2021) & (US$ Million)
Table 158. Middle East and Africa Peptide Cancer Vaccine Revenue by Country (2022-2027) & (US$ Million)
Table 159. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2016-2021) & (K Doses)
Table 160. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2016-2021) & (K Doses)
Table 161. Peptide Cancer Vaccine Key Raw Materials, Industry Status and Trend
Table 162. Peptide Cancer Vaccine Key Raw Materials and Upstream Suppliers
Table 163. Peptide Cancer Vaccine Clients Status and Trend
Table 164. Peptide Cancer Vaccine Typical Clients
Table 165. Peptide Cancer Vaccine Distributors
Table 166. Key Drivers: Impact Analysis (2022-2027)
Table 167. Peptide Cancer Vaccine Market Drivers
Table 168. Peptide Cancer Vaccine Market Opportunities
Table 169. Peptide Cancer Vaccine Market Challenges
Table 170. Peptide Cancer Vaccine Market Restraints
Table 171. Peptide Cancer Vaccine Porter's Five Forces Analysis
Table 172. Research Programs/Design for This Report
Table 173. Key Data Information from Secondary Sources
Table 174. Key Data Information from Primary Sources
List of Figures
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Sales Market Share by Type in 2021 & 2027
Figure 3. ITK-1 Product Picture
Figure 4. GRN-1201 Product Picture
Figure 5. TPIV200 Product Picture
Figure 6. TPIV110 Product Picture
Figure 7. UV1 Product Picture
Figure 8. Galinpepimut-S Product Picture
Figure 9. TARP 27-35 Product Picture
Figure 10. HER-Vaxx Product Picture
Figure 11. Vx-001 Product Picture
Figure 12. Global Peptide Cancer Vaccine Sales Market Share by Application in 2021 & 2027
Figure 13. Breast Cancer Examples
Figure 14. Lung Cancer Examples
Figure 15. Melanoma Examples
Figure 16. Prostate Cancer Examples
Figure 17. Others Examples
Figure 18. Peptide Cancer Vaccine Report Years Considered
Figure 19. Global Peptide Cancer Vaccine Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 20. Global Peptide Cancer Vaccine Market Size 2016-2027 (US$ Million)
Figure 21. Global Peptide Cancer Vaccine Sales 2016-2027 (K Units)
Figure 22. Global Peptide Cancer Vaccine Market Size Market Share by Region: 2021 Versus 2027
Figure 23. Global Peptide Cancer Vaccine Sales Market Share Forecast by Region (2016-2027)
Figure 24. Global Peptide Cancer Vaccine Revenue Market Share by Region (2016-2027)
Figure 25. Global Peptide Cancer Vaccine Sales Share by Manufacturer in 2020
Figure 26. Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 27. Global Peptide Cancer Vaccine Sales Market Share Forecast by Type (2016-2027)
Figure 28. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Type (2016-2027)
Figure 29. Peptide Cancer Vaccine Average Selling Price (ASP) by Type (2016-2021) & (USD/Unit)
Figure 30. Global Peptide Cancer Vaccine Sales Market Share Forecast by Application (2016-2027)
Figure 31. Global Peptide Cancer Vaccine Revenue Market Share Forecast by Application (2016-2027)
Figure 32. Peptide Cancer Vaccine Average Selling Price (ASP) by Application (2016-2021) & (USD/Unit)
Figure 33. North America Peptide Cancer Vaccine Revenue 2016-2027 (US$ Million)
Figure 34. North America Peptide Cancer Vaccine Sales Market Share by Type (2016-2021)
Figure 35. North America Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Figure 36. Asia-Pacific Peptide Cancer Vaccine Revenue 2016-2027 (US$ Million)
Figure 37. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Region (2016-2027)
Figure 38. Asia-Pacific Peptide Cancer Vaccine Revenue Market Share by Region (2016-2027)
Figure 39. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Type (2016-2021)
Figure 40. Asia-Pacific Peptide Cancer Vaccine Sales Market Share by Application (2016-2021)
Figure 41. Europe Peptide Cancer Vaccine Revenue Growth Rate 2016-2027 (US$ Mil

• Clinical Results in Diabetics To Be Boosted By Smart Artificial Beta Cells

For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…

• High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market

Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…

• Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market

The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …

• Foremost Trends In Global Pet Care Market

The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…

• China To Review Its Food Security Laws

China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…

Global BCG Vaccine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96

According to our LPI (LP Information) latest study, the global BCG Vaccine market size was valued at US$ 365.6 million in 2023. With growing demand in downstream market, the BCG Vaccine is forecast to a readjusted size of US$ 542.8 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global BCG Vaccine market. BCG Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing cost......

Global Peptide Cancer Vaccine Market Growth 2024-2030

Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115

According to our LPI (LP Information) latest study, the global Peptide Cancer Vaccine market size was valued at US$ 535 million in 2023. With growing demand in downstream market, the Peptide Cancer Vaccine is forecast to a readjusted size of US$ 1978.2 million by 2030 with a CAGR of 20.5% during review period. The research report highlights the growth potential of the global Peptide Cancer Vaccine market. Peptide Cancer Vaccine are expected to show stable growth in the future market. How......

Global Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 101

Market Overview of Global Cancer Vaccine market: According to our latest research, the global Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Cancer Vaccine market was estimated at USD 7198.2 million, and it's anticipated to reach USD 33936.62 million in 2028, with a CAGR of 29.49% during the forecast years. A cancer vaccine is a type of immunotherapy that boost the body's natural defenses by stimulating the immune system to recognize and cur......

Global Lung Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 12-Dec-2023        Price: US 3380 Onwards        Pages: 102

Market Overview of Global Lung Cancer Vaccines market: According to our latest research, the global Lung Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Lung Cancer Vaccines market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Lung Cancer Vaccines,A cancer vaccine for lung cance This report covers a research time span from 2018 to 2028, and ......

Global Cancer Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 07-Dec-2023        Price: US 3380 Onwards        Pages: 105

Market Overview of Global Cancer Vaccines market: According to our latest research, the global Cancer Vaccines market looks promising in the next 5 years. As of 2022, the global Cancer Vaccines market was estimated at USD 5773.14 million, and it's anticipated to reach USD 15406.41 million in 2028, with a CAGR of 17.77% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Cancer Vacci......

Global Dendritic Cell Cancer Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028

Published: 16-Nov-2023        Price: US 3380 Onwards        Pages: 110

Market Overview of Global Dendritic Cell Cancer Vaccine market: According to our latest research, the global Dendritic Cell Cancer Vaccine market looks promising in the next 5 years. As of 2022, the global Dendritic Cell Cancer Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Dendritic cells (DC) are one of the major antigen presenting cells found in lymphoid organs. The main fu......

Global BCG Vaccine Market Research Report 2023, Forecast to 2028

Published: 14-Nov-2023        Price: US 2680 Onwards        Pages: 135

BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......

Global BCG Vaccine Professional Survey Report 2023, Forecast to 2028

Published: 14-Nov-2023        Price: US 3280 Onwards        Pages: 105

BCG Vaccine is not given as part of the routine NHS vaccination schedule. It's given on the NHS only when a child or adult is thought to have an increased risk of coming into contact with TB. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage o......

Infectious Vaccine Collaboration and Licensing Deals 2016-2023

Published: 01-Nov-2023        Price: US 3995 Onwards        Pages: 300

Infectious Vaccine Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the infectious vaccine deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of infectious vaccine deals from 2016 to 2023. The report provides a detailed understanding and analysis of how and why companies enter infectious vaccine deals. These deals tend to be multicomponent, starting with......

We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s. Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors. Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business. Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision. Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us. Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done. Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )

• Ad Hoc
• Pay - as - you - go / Bucket Subscriptions
• Fixed Cost for #of reports
• Customize / Personalize as per your needs